TY - JOUR
T1 - Translocation of the proto-oncogene Bcl-6 in human glioblastoma multiforme
AU - Ruggieri, Simona
AU - Tamma, Roberto
AU - Marzullo, Andrea
AU - Annese, Tiziana
AU - Marinaccio, Christian
AU - Errede, Mariella
AU - Susca, Francesco C.
AU - Senetta, Rebecca
AU - Cassoni, Paola
AU - Vacca, Angelo
AU - Albano, Francesco
AU - Saracino, Chiara
AU - Notarangelo, Angelo
AU - Specchia, Giorgina
AU - Ribatti, Domenico
AU - Nico, Beatrice
PY - 2014
Y1 - 2014
N2 - Bcl-6 translocation is a genetic alteration that is commonly detected in Primary Central Nervous System Lymphoma. The role of this protein in cerebral tumors is unclear. In this study we investigated Bcl-6 translocation and its transcriptional and translational levels in formalin-fixed, paraffin-embedded cerebral tissue sections from glioblastoma (GBM), low-grade glioma (Astrocytoma grade II and III), and meningioma patients, and correlated them with apoptotic processes and p53 and caspase-3 expression. The results showed a frequency of 36.6% of Bcl-6 translocation in GBM patients and a decreased expression in low-grade glioma patients, correlated with the severity of the disease. Bcl-6 translocation induced an overexpression of both Bcl-6 protein and messenger in GBM, inhibiting apoptotic processes and caspases 3 expression. On the contrary, in low-grade gliomas and meningiomas Bcl-6 expression was reduced, resulting in an increase of apoptotic processes. Finally, p53 expression levels in brain tumors were comparable to Bcl-6 levels. Overall, these data demonstrate, for the first time, that the Bcl-6 gene translocates in GBM patients and that its translocation and expression are correlated with apoptosis inhibition, indicating a key role for this gene in the control of cellular proliferation. This study offers further insights into glioblastoma biology, and supports Bcl-6 as a new diagnostic marker to evaluate the disease severity.
AB - Bcl-6 translocation is a genetic alteration that is commonly detected in Primary Central Nervous System Lymphoma. The role of this protein in cerebral tumors is unclear. In this study we investigated Bcl-6 translocation and its transcriptional and translational levels in formalin-fixed, paraffin-embedded cerebral tissue sections from glioblastoma (GBM), low-grade glioma (Astrocytoma grade II and III), and meningioma patients, and correlated them with apoptotic processes and p53 and caspase-3 expression. The results showed a frequency of 36.6% of Bcl-6 translocation in GBM patients and a decreased expression in low-grade glioma patients, correlated with the severity of the disease. Bcl-6 translocation induced an overexpression of both Bcl-6 protein and messenger in GBM, inhibiting apoptotic processes and caspases 3 expression. On the contrary, in low-grade gliomas and meningiomas Bcl-6 expression was reduced, resulting in an increase of apoptotic processes. Finally, p53 expression levels in brain tumors were comparable to Bcl-6 levels. Overall, these data demonstrate, for the first time, that the Bcl-6 gene translocates in GBM patients and that its translocation and expression are correlated with apoptosis inhibition, indicating a key role for this gene in the control of cellular proliferation. This study offers further insights into glioblastoma biology, and supports Bcl-6 as a new diagnostic marker to evaluate the disease severity.
KW - Bcl-6
KW - Brain tumors
KW - Glioma
KW - Tumor progression
UR - http://www.scopus.com/inward/record.url?scp=84908375630&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908375630&partnerID=8YFLogxK
U2 - 10.1016/j.canlet.2014.06.017
DO - 10.1016/j.canlet.2014.06.017
M3 - Article
C2 - 25038272
AN - SCOPUS:84908375630
VL - 353
SP - 41
EP - 51
JO - Cancer Letters
JF - Cancer Letters
SN - 0304-3835
IS - 1
ER -